Zwart Hub
Faculty of Science, Radboud University Nijmegen, Department of Philosophy & Science Studies, Centre for Society & Genomics Institute for Science, Innovation & Society, P.O. Box 9010, 6500 GL Nijmegen, The Netherlands.
J Bioeth Inq. 2010 Sep;7(3):299-312. doi: 10.1007/s11673-010-9248-0. Epub 2010 Jul 9.
The Human Genome Project (HGP) is regarded by many as one of the major scientific achievements in recent science history, a large-scale endeavour that is changing the way in which biomedical research is done and expected, moreover, to yield considerable benefit for society. Thus, since the completion of the human genome sequencing effort, a debate has emerged over the question whether this effort merits to be awarded a Nobel Prize and if so, who should be the one(s) to receive it, as (according to current procedures) no more than three individuals can be selected. In this article, the HGP is taken as a case study to consider the ethical question to what extent it is still possible, in an era of big science, of large-scale consortia and global team work, to acknowledge and reward individual contributions to important breakthroughs in biomedical fields. Is it still viable to single out individuals for their decisive contributions in order to reward them in a fair and convincing way? Whereas the concept of the Nobel prize as such seems to reflect an archetypical view of scientists as solitary researchers who, at a certain point in their careers, make their one decisive discovery, this vision has proven to be problematic from the very outset. Already during the first decade of the Nobel era, Ivan Pavlov was denied the Prize several times before finally receiving it, on the basis of the argument that he had been active as a research manager (a designer and supervisor of research projects) rather than as a researcher himself. The question then is whether, in the case of the HGP, a research effort that involved the contributions of hundreds or even thousands of researchers worldwide, it is still possible to "individualise" the Prize? The "HGP Nobel Prize problem" is regarded as an exemplary issue in current research ethics, highlighting a number of quandaries and trends involved in contemporary life science research practices more broadly.
人类基因组计划(HGP)被许多人视为近代科学史上的重大科学成就之一,这是一项大规模的努力,正在改变生物医学研究的方式,而且有望为社会带来巨大益处。因此,自人类基因组测序工作完成以来,就出现了一场争论,即这项工作是否值得授予诺贝尔奖,如果值得,那么(根据现行程序,获奖者不超过三人)谁应该获奖。在本文中,以人类基因组计划为例,探讨在大科学、大规模财团合作和全球团队协作的时代,在何种程度上仍有可能认可和奖励对生物医学领域重大突破做出的个人贡献这一伦理问题。为了以公平且令人信服的方式奖励个人,挑选出做出决定性贡献的个人是否仍然可行?诺贝尔奖的概念本身似乎反映了一种典型观点,即科学家是孤独的研究者,在其职业生涯的某个时刻做出一项决定性发现,但从一开始这种观点就存在问题。早在诺贝尔奖时代的第一个十年,伊万·巴甫洛夫就多次被拒,最终获奖时的理由是他一直担任研究管理者(研究项目的设计者和监督者)而非研究者本人。那么问题在于,就涉及全球数百甚至数千名研究人员贡献的人类基因组计划而言,是否仍然有可能将该奖项“个人化”?“人类基因组计划诺贝尔奖问题”被视为当前研究伦理中的一个典型问题,更广泛地凸显了当代生命科学研究实践中涉及的一些困境和趋势。